What type of study is this?

This is a Human Clinical Trial study.

December 8, 2025BloodOpen Access

Impact of 7-day versus standard venetoclax exposure in combination with azacitidine in frontline AML settings: A real-world analysis from the venaura retrospective multicenter study

View Full Paper

Ask AI

Bookmark

Authors

Real-world analysis shows 7-day venetoclax regimen has lower response rates in acute myeloid leukemia, implying caution with abbreviated schedules.

Short-course venetoclax treatment resulted in a lower overall response rate compared to standard treatment.
Response rates were 40% for short-course versus 57% for standard, indicating significant differences based on duration.
Data were collected retrospectively from 10 centers across France using the VENAURA registry with 775 patients.
Findings highlight the importance of assessing patient eligibility and potential risks for those receiving shorter treatment schedules.

Tauveron-Jalenques et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Real-world analysis shows 7-day venetoclax regimen has lower response rates in acute myeloid leukemia, implying caution with abbreviated schedules.

Short-course venetoclax treatment resulted in a lower overall response rate compared to standard treatment.
Response rates were 40% for short-course versus 57% for standard, indicating significant differences based on duration.
Data were collected retrospectively from 10 centers across France using the VENAURA registry with 775 patients.
Findings highlight the importance of assessing patient eligibility and potential risks for those receiving shorter treatment schedules.

Tauveron-Jalenques et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark